acute coronary syndrome

     

mechanismtreatment Demonstrated benefit and harm k      
anti-anginal drugsranolazine

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsapixaban

versus placebo or control

No demonstrated result for efficacy

apixaban inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in APPRAISE-1 (10mg od), 2009

apixaban inferior to placebo in terms of TIMI major or minor bleeding not related to CABG in APPRAISE 2, 2011

apixaban inferior to placebo in terms of major bleeding in APPRAISE 2, 2011

apixaban inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in APPRAISE 2, 2011

apixaban inferior to placebo in terms of any bleeding in APPRAISE 2, 2011

apixaban inferior to placebo in terms of major or minor bleeding in APPRAISE 2, 2011

3 trialsmeta-analysis
antithromboticsargatroban

versus heparin

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsaspirin

versus placebo or control

No demonstrated result for efficacy

8 trialsmeta-analysis
antithromboticsatopaxar

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticsbivalirudin

versus

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticsbivalirudin

versus eptifibatide + heparin

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsbivalirudin

versus heparin

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticsbivalirudin

versus heparin+aGP2b3a

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticsclopidogrel

versus placebo

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsclopidogrel

versus aspirin

No demonstrated result for efficacy

clopidogrel + aspirin inferior to aspirin in terms of Major bleeds in CURE, 2001

1 trialmeta-analysis
antithromboticsclopidogrel

versus clopidogrel

No demonstrated result for efficacy

clopidogrel high-dose regimen inferior to clopidogrel standard-dose in terms of Major bleeds in CURRENT OASIS 7 (clopidogrel), 2010

1 trialmeta-analysis
antithromboticscoumadin

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticscoumadin

versus antiplatelet drugs

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsdabigatran

versus placebo and control

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsdalteparin

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
antithromboticsdalteparin

versus UFH

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsdipyridamol

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsEfegatran

versus heparin

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsenoxaparin

versus

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsenoxaparin

versus LMWH

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsenoxaparin

versus UFH

No demonstrated result for efficacy

enoxaparin inferior to UFH (on top of aspirin) in terms of minor bleeding in ESSENCE, 1997

enoxaparin inferior to UFH (on top of aspirin) in terms of minor bleeding in TIMI 11 B (short term), 1998

enoxaparin inferior to UFH (on top of aspirin) in terms of major bleeding in SYNERGY, 2005

enoxaparin inferior to UFH (on top of aspirin) in terms of minor bleeding in INTERACT, 2006

enoxaparin inferior to UFH (on top of aspirin) in terms of major bleeding in TIMI 11 B (long term), 1998

enoxaparin inferior to UFH (on top of aspirin) in terms of minor bleeding in TIMI 11 B (long term), 1998

5 trialsmeta-analysis
antithromboticsfondaparinux

versus LMWH

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticshirudin

versus heparin

No demonstrated result for efficacy

7 trialsmeta-analysis
antithromboticsinogatran

versus heparin

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsnadroparin

versus UFH

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticsotamixaban

versus UFH

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsprasugrel

versus clopidogrel

No demonstrated result for efficacy

prasugrel inferior to clopidogrel in terms of all bleeding (major and minor) in TRITON-TIMI 38, 2007

prasugrel inferior to clopidogrel in terms of Major bleeds in TRITON-TIMI 38, 2007

prasugrel inferior to clopidogrel in terms of fatal bleeding in TRITON-TIMI 38, 2007

2 trialsmeta-analysis
antithromboticsrivaroxaban

versus placebo or control

No demonstrated result for efficacy

rivaroxaban 2.5mg inferior to placebo in terms of major bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 2.5mg inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 2.5mg inferior to placebo in terms of any bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 2.5mg inferior to placebo in terms of major or minor bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of major bleeding in ATLAS ACS 2 - TIMI 51 (5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in ATLAS ACS 2 - TIMI 51 (5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of any bleeding in ATLAS ACS 2 - TIMI 51 (5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of major bleeding in ATLAS ACS-TIMI 46 (5mg), 2009

rivaroxaban 5mg inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in ATLAS ACS-TIMI 46 (5mg), 2009

4 trialsmeta-analysis
antithromboticssulfinpyrazone

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsticagrelor

versus clopidogrel

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticsticlopidine

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
antithromboticstrapidil

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticstriflusal

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticsUFH

versus placebo or control

No demonstrated result for efficacy

10 trialsmeta-analysis
antithromboticsUFH

versus aspirin

No demonstrated result for efficacy

1 trialmeta-analysis
antithromboticswarfarin

versus placebo or control

No demonstrated result for efficacy

warfarin inferior to control (on top of aspirin) in terms of major bleeding in OASIS-2 Warfarin Substudy, 2001

warfarin inferior to control (on top of aspirin) in terms of major bleeding in CHAMP, 2002

warfarin inferior to control (on top of aspirin) in terms of extracranial major bleeding in CHAMP, 2002

warfarin inferior to control (on top of aspirin) in terms of major bleeding in WARIS, 2002

warfarin inferior to control (on top of aspirin) in terms of extracranial major bleeding in WARIS, 2002

warfarin inferior to control (on top of aspirin) in terms of major bleeding in LoWASA, 2004

warfarin inferior to control (on top of aspirin) in terms of extracranial major bleeding in LoWASA, 2004

14 trialsmeta-analysis
antithromboticsximelagatran

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
calcium channel blockersdiltiazem

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
calcium channel blockersnifedipine

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
cholesterol lowering interventionatorvastatin

versus placebo or control

No demonstrated result for efficacy

3 trialsmeta-analysis
cholesterol lowering interventionatorvastatin

versus statin

No demonstrated result for efficacy

1 trialmeta-analysis
cholesterol lowering interventionfluvastatin

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
cholesterol lowering interventionpravastatin

versus placebo or control

No demonstrated result for efficacy

6 trialsmeta-analysis
cholesterol lowering interventionsimvastatin

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis
myocardial revascularizationanistreplase

versus placebo or control

No demonstrated result for efficacy

anistreplase inferior to placebo in terms of bleeding in UNASEM, 1992

1 trialmeta-analysis
myocardial revascularizationt-pa

versus placebo or control

No demonstrated result for efficacy

t-PA inferior to placebo in terms of bleeding in Williams, 1990

10 trialsmeta-analysis
nitratesnitroglycerin

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis